Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.3466
Abstract: Importance Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT. Objective… read more here.
Keywords: bevacizumab cetuximab; left sided; cetuximab; mortality ... See more keywords
Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Healthcare"
DOI: 10.3390/healthcare10020217
Abstract: Proper medication management is crucial in metastatic colorectal cancer because of its substantially low survival rate. There has been advancing evidence on the efficacy of the two most prescribed targeted agents (bevacizumab and cetuximab); however,… read more here.
Keywords: adverse events; metastatic colorectal; bevacizumab cetuximab; first line ... See more keywords